The ENABLE Study (Equitability of Insurance Access to Biologics and its Impact on Effectiveness)

Print

Details of Research

Contact: Reka Thanabalan, Research Coordinator
416-586-4800 ext 7636
rthanabalan@mtsinai.on.ca

Primary Investigator: Dr. Geoffrey Nguyen

Co-investigators: Drs. Justina Sam, Smita Halder, Richmond Sy, Nilesh Chande

Enrolment: Ongoing

Objective: Objective is to formally assess the time interval from application for coverage of anti-TNF therapy (including Remicade and Humira) to first dose for privately vs. publicly insured patients with Inflammatory Bowel Disease (IBD) and to study whether potential delays in access to this therapy will have an effect on health outcomes such as hospitalization or surgery.

Expectation: If this study were to show that inequalities in access to drugs exists based on type of insurance, we can take steps to work with Ontario health policy makers to reform the public drug coverage program.

Eligibility: Biologic Naïve patients over 18 years of age who have a confirmed diagnosis of IBD (either Crohn's Disease or Ulcerative Colitis) and have applied for Remicade or Humira therapy after January 1, 2007 with one of the gastroenterologists at Mount Sinai Hospital.

Exclusion:


Participation: